Review
Pharmacology & Pharmacy
Varvara Choida, Margaret Hall-Craggs, Bethany R. Jebson, Corinne Fisher, Maria Leandro, Lucy R. Wedderburn, Coziana Ciurtin
Summary: This study evaluated the role of biomarkers in predicting and assessing biologic treatment response and clinical remission in JIA, proposing new strategies for biomarker use. Various types of biomarkers were reviewed, identifying candidates with potential clinical utility and highlighting the need for new biomarker discovery and improved clinical applications.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Rheumatology
Roberta Berard, Hon Yan Ng, Andrea Human, David Piskin, Muhammed Dhalla, Chloe Gottlieb, Michelle Batthish, Gaelle Chedeville, Christina Forest, Eric Fortin, Jane Gardiner, Kerstin Gerhold, Andre Jastrzebski, Bianca Lang, Paivi M. H. Miettunen, Sabrina Morgenstern, Marie-Paule Morin, Alan Rosenberg, Dax G. Rumsey, Carlos E. Solarte, Nasrin Tehrani, Karen Watanabe Duffy, Jordi Pardo Pardo, Glen S. Hazlewood, Deborah M. Levy
Summary: The objective of this study was to develop Canadian recommendations for the screening, monitoring, and treatment of uveitis associated with juvenile idiopathic arthritis (JIA). The study used the GRADE-ADOLOPMENT approach and involved a working group of healthcare professionals and patient representatives who reviewed existing recommendations and developed evidence-based recommendations specific to the Canadian context. The recommendations were generated through a survey, online discussions, and a virtual meeting.
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Melissa L. Mannion, Fenglong Xie, Daniel B. Horton, Sarah Ringold, Colleen K. Correll, Anne Dennos, Timothy Beukelman
Summary: Biologic medications have greatly improved disease control and outcomes for patients with juvenile idiopathic arthritis (JIA), but a substantial number of patients may require switching to a second biologic. The time to switch has decreased in recent years, and further studies are needed to evaluate outcomes and optimal timing of biologic switching.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Pediatrics
Mia Lindegaard Pedersen, Amalie Neve-Graesboll, Troels Herlin, Mia Glerup
Summary: This retrospective observational study aimed to describe the pattern, timing, frequency, and reasons for biologic disease-modifying antirheumatic drug (bDMARD) switching among children diagnosed with non-systemic juvenile idiopathic arthritis (JIA). The study found that over one third of patients underwent at least one bDMARD switch during the median follow-up period, primarily due to inefficacy.
PEDIATRIC RHEUMATOLOGY
(2023)
Editorial Material
Rheumatology
Marc Feldmann, Ravinder N. Maini, Enrique R. Soriano, Vibeke Strand, Tsutomu Takeuchi
Summary: In this Viewpoint article, five rheumatology researchers discuss how biologic therapy has transformed clinical practice and reflect on their own experiences, past and current challenges, and the future prospects of biologic drugs.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Article
Ophthalmology
Justine R. Smith, Janet M. Matthews, Diana Conrad, Anthony J. Hall, Rachael L. Niederer, Davinder Singh-Grewal, Mei-Ling Tay-Kearney, Jane M. Wells, Sophia L. Zagora, Peter J. McCluskey
Summary: The Australian and New Zealand-based uveitis-specialized ophthalmologists have developed 18 consensus statements for managing chronic anterior uveitis in children with JIA, providing regionally applicable advice for ophthalmic care.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2021)
Article
Medicine, General & Internal
Monika Ostrowska, Emil Michalski, Piotr Gietka, Malgorzata Manczak, Magdalena Posadzy, Iwona Sudol-Szopinska
Summary: This study compared MRI findings between patients clinically suspected of Juvenile Idiopathic Arthritis (JIA) and patients with ankle arthralgia of unknown cause. The results showed that inflammatory features were observed on MRI, with tenosynovitis being significantly more common in JIA patients. However, the MRI summarized score did not effectively differentiate between JIA and non-JIA patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Rheumatology
Yavuz Ozer, Mehmet Yildiz, Hande Turan, Gurkan Tarcin, Dilek Bingol Aydin, Aybuke Gunalp, Fatih Haslak, Elif Kilic Konte, Esma Aslan, Oya Koker, Elvan Bayramoglu, Sezgin Sahin, Amra Adrovic, Kenan Barut, Ozgur Kasapcopur, Olcay Evliyaoglu
Summary: This study aims to evaluate the effect of juvenile idiopathic arthritis (JIA) and biologic disease-modifying anti-rheumatic drugs (bDMARDs) on ovarian reserve in children. The results show that bDMARDs are reassuring in terms of ovarian reserve in girls with JIA, as they have little impact on anti-Mullerian hormone (AMH).
CLINICAL RHEUMATOLOGY
(2023)
Review
Rheumatology
Peter Stoustrup, Cory M. Resnick, Shelly Abramowicz, Thomas K. Pedersen, Ambra Michelotti, Annelise Kuseler, Bernd Koos, Carlalberta Verna, Ellen B. Nordal, Eric J. Granquist, Josefine Mareile Halbig, Kasper D. Kristensen, Leonard B. Kaban, Linda Z. Arvidsson, Lynn Spiegel, Matthew L. Stoll, Melissa A. Lerman, Mia Glerup, Patrizia Defabianis, Paula Frid, Per Alstergren, Randy Q. Cron, Sarah Ringold, Sven Erik Norholt, Timo Peltomaki, Tore A. Larheim, Troels Herlin, Zachary S. Peacock, Christian J. Kellenberger, Marinka Twilt
Summary: This study aimed to develop interdisciplinary recommendations for the management of orofacial manifestations of juvenile idiopathic arthritis (JIA) and to create a future research agenda for the treatment of temporomandibular joint (TMJ) arthritis in children with JIA. The recommendations were developed through online surveying, literature review, consensus meetings, and Delphi study iterations. Twelve recommendations and a future research agenda were outlined, filling an important gap in current clinical practice.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Rheumatology
Jennifer J. Y. Lee, Simon W. M. Eng, Jaime Guzman, Ciaran M. Duffy, Lori B. Tucker, Kiem Oen, Rae S. M. Yeung, Brian M. Feldman
Summary: This study compared the ILAR and PRINTO JIA classification criteria in a cohort of JIA patients. The results showed that a large proportion of JIA patients were unclassifiable using the PRINTO criteria, and the alignment with clinicobiologic subtypes and adult forms of arthritis was not as good as the ILAR criteria.
ARTHRITIS & RHEUMATOLOGY
(2022)
Article
Pediatrics
Violetta Opoka-Winiarska, Joanna Lipinska, Arkadiusz Michalak, Jacek Burzynski, Olga Kadziolka, Elzbieta Smolewska
Summary: This study aimed to assess the safety of COVID-19 vaccines in children with JIA. A cohort study of 43 children with JIA found that COVID-19 vaccines were safe for these patients and did not interfere with JIA treatment or exacerbate disease symptoms.
FRONTIERS IN PEDIATRICS
(2023)
Article
Rheumatology
Lianne Kearsley-Fleet, Eileen Baildam, Michael W. Beresford, Sharon Douglas, Helen E. Foster, Taunton R. Southwood, Kimme L. Hyrich, Coziana Ciurtin
Summary: This analysis identified factors associated with successful cessation of biologics for remission in JIA as absence of uveitis, prior treatment with tocilizumab, and starting biologics earlier in the disease course.
Article
Multidisciplinary Sciences
Juan Carlos Nieto-Gonzalez, Laura Trives-Folguera, Alejandra Melgarejo-Ortuno, Aranzazu Ais, Belen Serrano-Benavente, Maria Sanjurjo, Jose Maria Alvaro-Gracia, Indalecio Monteagudo Saez
Summary: This study found that both persistence and adherence to biological therapy were remarkably high in JIA patients, and adherence to biological treatments could be related to a higher probability of patients achieving remission criteria within 6 months.
SCIENTIFIC REPORTS
(2021)
Review
Rheumatology
Vibeke Strand, Joao Goncalves, John D. Isaacs
Summary: Biologic agents have become crucial in treating inflammatory rheumatic diseases, but their immunogenicity can impact treatment response and adverse events. Immunogenicity testing is becoming part of routine clinical management in some fields, with the cost-effectiveness in rheumatology still being studied.
NATURE REVIEWS RHEUMATOLOGY
(2021)
Article
Multidisciplinary Sciences
Willemijn F. C. de Sonnaville, Michel H. Steenks, Nicolaas P. A. Zuithoff, Nico M. Wulffraat, Antoine J. W. P. Rosenberg, Caroline M. Speksnijder
Summary: This cross-sectional study aimed to determine the reliability of AMVBF in children with JIA and healthy children. The results showed that AMVBF measurements have good to excellent reliability in children with JIA and moderate to excellent reliability in healthy children. Values above 11.4N might be a clinically relevant change over time in children with JIA.
Article
Rheumatology
Daniel B. Horton, Jomaira Salas, Aleksandra Wec, Melanie Kohlheim, Pooja Kapadia, Timothy Beukelman, Alexis Boneparth, Ky Haverkamp, Melissa L. Mannion, L. Nandini Moorthy, Sarah Ringold, Marsha Rosenthal
Summary: When deciding whether to stop medications when JIA is inactive, patients and caregivers consider competing risks between disease activity and treatment, as well as factors such as concerns about JIA, treatment-related complications, sense of normalcy and safety, and uncertainty about future harms. They also rely on trust in healthcare providers and other information sources for decision-making.
ARTHRITIS CARE & RESEARCH
(2021)
Article
Rheumatology
Justine Maller, Emily Fox, K. T. Park, Sarah Sertial Paul, Kevin Baszis, Charlotte Borocco, Sampath Prahalad, Pierre Quartier, Adam Reinhardt, Dieneke Schonenberg-Meinema, Lauren Shipman-Duensing, Maria Teresa Terreri, Julia Simard, Idit Lavi, Elizabeth Chalom, Joyces Hsu, Devy Zisman, Elizabeth D. Mellins
Summary: The occurrence of inflammatory bowel disease in the setting of systemic juvenile idiopathic arthritis is rare, with patients showing favorable response to tumor necrosis factor-alpha inhibitors.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Daniel B. Horton, Fenglong Xie, Lang Chen, Melissa L. Mannion, Jeffrey R. Curtis, Brian L. Strom, Timothy Beukelman
Summary: This study found that children taking high-dose oral glucocorticoids have a higher relative risk of newly treated VTE, diabetes, and especially hypertension, but a lower absolute risk.
AMERICAN JOURNAL OF EPIDEMIOLOGY
(2021)
Article
Rheumatology
Melissa L. Mannion, Fenglong Xie, Daniel B. Horton, Sarah Ringold, Colleen K. Correll, Anne Dennos, Timothy Beukelman
Summary: Biologic medications have greatly improved disease control and outcomes for patients with juvenile idiopathic arthritis (JIA), but a substantial number of patients may require switching to a second biologic. The time to switch has decreased in recent years, and further studies are needed to evaluate outcomes and optimal timing of biologic switching.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Rheumatology
Jordan T. Jones, Chelsey Smith, Mara L. Becker, Daniel Lovell
Summary: This study found that patients with Down syndrome-associated arthritis (DA) and juvenile idiopathic arthritis (JIA) had similar therapeutic exposure, but DA patients had higher rates of adverse events and treatment ineffectiveness. At the last visit, DA patients had a greater disease burden compared to JIA patients. More research is needed to determine differences in pathophysiology and optimal therapeutic approaches.
ARTHRITIS CARE & RESEARCH
(2021)
Article
Rheumatology
Dax G. Rumsey, Aimee Lougee, Roland Matsouaka, David H. Collier, Laura E. Schanberg, Jennifer Schenfeld, Natalie J. Shiff, Matthew L. Stoll, Scott Stryker, Pamela F. Weiss, Timothy Beukelman
Summary: This study described characteristics of over 900 children with ERA or juvenile PsA, highlighting high biologic use, especially in those with sacroiliitis. Equal sex representation was found in children with sacroiliitis.
ARTHRITIS CARE & RESEARCH
(2021)
Article
Rheumatology
Ishaan Dave, Brandon Estroff, Talia Gergely, Christina A. Rostad, Lori A. Ponder, Courtney McCracken, Sampath Prahalad
Summary: Children with juvenile idiopathic arthritis are more likely to be born in the winter, specifically in the month of January, compared to the general population. These findings suggest that seasonal variations during gestation and early postnatal periods may play a role in the development of JIA.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Pediatrics
Nayimisha Balmuri, William Daniel Soulsby, Victoria Cooley, Linda Gerber, Erica Lawson, Susan Goodman, Karen Onel, Bella Mehta
Summary: The study found that higher community poverty levels were associated with a longer time to pediatric rheumatologist presentation after symptom onset in children with polyarticular juvenile idiopathic arthritis.
PEDIATRIC RHEUMATOLOGY
(2021)
Article
Pediatrics
Timothy Beukelman, Aimee Lougee, Roland A. Matsouaka, David Collier, Dax G. Rumsey, Jennifer Schenfeld, Scott Stryker, Marinka Twilt, Yukiko Kimura
Summary: This study characterizes contemporary patterns of ETN use in the CARRA Registry. Treatment was largely in keeping with American College of Rheumatology guidelines.
PEDIATRIC RHEUMATOLOGY
(2021)
Article
Pediatrics
William Daniel Soulsby, Nayimisha Balmuri, Victoria Cooley, Linda M. Gerber, Erica Lawson, Susan Goodman, Karen Onel, Bella Mehta
Summary: Social determinants of health have a significant impact on the outcomes of rheumatoid arthritis treatment. Our study found that community poverty level, race/ethnicity, and economic factors are associated with disease activity and functional disability in polyarticular juvenile idiopathic arthritis patients.
PEDIATRIC RHEUMATOLOGY
(2022)
Article
Pediatrics
Meghan E. Ryan, Andrew Warmin, Bryce A. Binstadt, Colleen K. Correll, Emily Hause, Patricia Hobday, Alison Lerman, Shawn A. Mahmud, Mona M. Riskalla, Zachary Shaheen, Richard K. Vehe, Danielle R. Bullock
Summary: The study aimed to improve documentation of critical data elements by implementing quality improvement methods, and found that virtual visits had lower data capture rates compared to in-person visits.
PEDIATRIC RHEUMATOLOGY
(2022)
Article
Pediatrics
Shawn A. Mahmud, Danielle R. Bullock, Colleen K. Correll, Patricia M. Hobday, Mona M. Riskalla, Richard K. Vehe, Bryce A. Binstadt
Summary: Non-criteria antiphospholipid antibodies (NC-aPL) are associated with pediatric patients with antiphospholipid syndrome (APS), and doctors should consider the existence of NC-aPL when there is a high suspicion and routine antiphospholipid antibody tests are negative. Currently, there are no guidelines for NC-aPL in children or adults, so more data needs to be collected.
PEDIATRIC RHEUMATOLOGY
(2022)
Article
Health Care Sciences & Services
Bayardo Garay, Denise Erlanson, Bryce A. Binstadt, Colleen K. Correll, Nora Fitzsimmons, Patricia M. Hobday, Allison Hudson, Shawn Mahmud, Mona M. Riskalla, Sara Kramer, Sheng Xiong, Richard K. Vehe, Danielle R. Bullock
Summary: By implementing a checkout sheet and staggered start times, this study effectively reduced patient wait time in a paediatric rheumatology clinic, leading to a decrease in variation and mean wait time.
